- Home
- SGLY vs AZTR Comparison
SGLY vs AZTR Comparison
Compare SGLY & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- AZTR
- Stock Information
- Founded
- SGLY 2001
- AZTR 2014
- Country
- SGLY United States
- AZTR United States
- Employees
- SGLY N/A
- AZTR N/A
- Industry
- SGLY
- AZTR Biotechnology: Pharmaceutical Preparations
- Sector
- SGLY
- AZTR Health Care
- Exchange
- SGLY Nasdaq
- AZTR Nasdaq
- Market Cap
- SGLY 3.9M
- AZTR 4.0M
- IPO Year
- SGLY 2008
- AZTR 2023
- Fundamental
- Price
- SGLY $1.02
- AZTR $0.26
- Analyst Decision
- SGLY
- AZTR
- Analyst Count
- SGLY 0
- AZTR 0
- Target Price
- SGLY N/A
- AZTR N/A
- AVG Volume (30 Days)
- SGLY 52.7K
- AZTR 4.6M
- Earning Date
- SGLY 08-26-2025
- AZTR 08-11-2025
- Dividend Yield
- SGLY N/A
- AZTR N/A
- EPS Growth
- SGLY N/A
- AZTR N/A
- EPS
- SGLY N/A
- AZTR N/A
- Revenue
- SGLY $2,172,036.00
- AZTR $7,500.00
- Revenue This Year
- SGLY N/A
- AZTR N/A
- Revenue Next Year
- SGLY N/A
- AZTR N/A
- P/E Ratio
- SGLY N/A
- AZTR N/A
- Revenue Growth
- SGLY N/A
- AZTR N/A
- 52 Week Low
- SGLY $0.54
- AZTR $0.23
- 52 Week High
- SGLY $7.65
- AZTR $12.00
- Technical
- Relative Strength Index (RSI)
- SGLY 51.57
- AZTR 45.07
- Support Level
- SGLY $1.02
- AZTR $0.25
- Resistance Level
- SGLY $1.16
- AZTR $0.27
- Average True Range (ATR)
- SGLY 0.08
- AZTR 0.02
- MACD
- SGLY -0.01
- AZTR -0.00
- Stochastic Oscillator
- SGLY 50.00
- AZTR 24.85
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About AZTR Azitra Inc
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.